Literature DB >> 33786216

Polymicrobial Pseudomonas Plus Candida Parapsilosis Endocarditis in an Injection Drug User: Considerations for Diagnosis and Management.

Maninder Kaur1, Parminder Virdi1, Ramanjit Kaur2, Aiden Abidov2, Diane L Levine1.   

Abstract

Fungal endocarditis (FE) is a potentially lethal condition and its diagnosis can be challenging due to the low yield from blood cultures. FE should be suspected in patients with associated risk factors despite the identification of positive bacterial blood cultures. The common risk factors for FE discussed in the literature are total parenteral nutrition, immune suppression, prior antimicrobial therapy, intravenous drug addiction, and cardiac surgery. In this report, we discuss a patient who had positive blood cultures for Pseudomonas but was found to have Candida parapsilosis on valve culture. Physicians need to maintain a high index of suspicion for co-infective endocarditis in this patient population.
Copyright © 2021, Kaur et al.

Entities:  

Keywords:  cd4 lymphocytopenia; fungal endocarditis; injection drug use; pseudomonas aeruginosa and candida parapsilosis

Year:  2021        PMID: 33786216      PMCID: PMC7993063          DOI: 10.7759/cureus.13507

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  11 in total

1.  Diagnosis, management and outcome of Candida endocarditis.

Authors:  A Lefort; L Chartier; B Sendid; M Wolff; J-L Mainardi; I Podglajen; M Desnos-Ollivier; A Fontanet; S Bretagne; O Lortholary
Journal:  Clin Microbiol Infect       Date:  2012-02-13       Impact factor: 8.067

2.  Trends in Drug Use-Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017: A Study of Statewide Discharge Data.

Authors:  Asher J Schranz; Aaron Fleischauer; Vivian H Chu; Li-Tzy Wu; David L Rosen
Journal:  Ann Intern Med       Date:  2018-12-04       Impact factor: 25.391

Review 3.  Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy.

Authors:  F Kate Gould; David W Denning; Tom S J Elliott; Juliet Foweraker; John D Perry; Bernard D Prendergast; Jonathan A T Sandoe; Michael J Spry; Richard W Watkin
Journal:  J Antimicrob Chemother       Date:  2011-11-14       Impact factor: 5.790

Review 4.  Fungal endocarditis: evidence in the world literature, 1965-1995.

Authors:  M E Ellis; H Al-Abdely; A Sandridge; W Greer; W Ventura
Journal:  Clin Infect Dis       Date:  2000-12-12       Impact factor: 9.079

5.  [Practice guidelines of the Spanish Society of Cardiology on endocarditis].

Authors:  F Vallés; M Anguita; M P Escribano; F Pérez Casar; H Pousibet; P Tornos; M Vilacosta
Journal:  Rev Esp Cardiol       Date:  2000-10       Impact factor: 4.753

Review 6.  Fungal endocarditis, 1995-2000.

Authors:  Lígia C Pierrotti; Larry M Baddour
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

7.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

8.  Acute endocarditis in intravenous drug users: a case report and literature review.

Authors:  Yan Ji; Lara Kujtan; Dawn Kershner
Journal:  J Community Hosp Intern Med Perspect       Date:  2012-04-30

9.  Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs.

Authors:  Alysse G Wurcel; Jordan E Anderson; Kenneth K H Chui; Sally Skinner; Tamsin A Knox; David R Snydman; Thomas J Stopka
Journal:  Open Forum Infect Dis       Date:  2016-07-26       Impact factor: 3.835

10.  Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network.

Authors:  Brandon J Webb; Jeffrey P Ferraro; Susan Rea; Stephanie Kaufusi; Bruce E Goodman; James Spalding
Journal:  Open Forum Infect Dis       Date:  2018-07-31       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.